Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Author affiliations: Ghent University, Merelbeke, Belgium (E. Vandoorn, A. Parys, K. Van Reeth); Ghent University and Ghent University Hospital, Ghent, Belgium (I. Leroux-Roels, G. Leroux-Roels); National Animal Disease Center, Ames, Iowa, USA (A. Vincent)
Humans and swine are susceptible to influenza A viruses (IAVs) of hemagglutinin (HA) subtypes H1 and H3, which are widespread in both species. Human IAVs frequently are transmitted to swine, after which the HA surface protein generally undergoes slower antigenic evolution (drift) in swine than in humans (13). Therefore, swine can be considered a reservoir for past human IAVs. Because antigenic drift variants of human IAVs replace each other over time, younger persons only have been exposed to more recent strains and human population immunity against older human IAVs gradually decreases (4). Consequently, human-origin swine IAVs (swIAVs) can be reintroduced into the human population after a certain period and cause a pandemic, as illustrated by the influenza A(H1N1)pdm09 virus (pH1N1) (5). The H1 of this swine-origin virus is related to the H1 of human seasonal H1N1 IAVs that circulated in 19181950. In 2009, only persons born before the 1950s had cross-reactive antibodies against H1N1 viruses, so a pandemic was possible (6,7).
The evolution of swIAVs is different from and more complex than that of human IAVs because of multiple introductions of human IAVs into swine and geographic separation of swine populations (8). H1 swIAV colloquial names indicate their origin and region of circulation. An improved classification system subdivides H1 swIAVs into 3 lineages and 28 clades on the basis of H1 nucleotide sequence homology (9). The lineages are 1A, 1B, and 1C, with the number representing the subtype (H1) and the letter representing the lineage. Clades and subclades are indicated with 13 digits. Classical swine lineage 1A contains IAVs with the human 1918 pandemic H1N1 virus as a common ancestor. Most clades are restricted to America and Asia, but pH1N1 viruses (1A.3.3.2) circulate in swine and humans worldwide. Human seasonal lineage 1B contains swIAVs with an H1 derived from human seasonal IAVs. These human-like H1 swIAVs emerged in Europe in the late 1980s and in North America in the early 2000s. Eurasian avian lineage 1C contains swIAVs that originated from avian IAVs. These avian-like swIAVs emerged in Europe in 1979 and spread to Asia in 1993 (1013). Apart from antigenic evolution in the HA, IAVs also can evolve via exchange of gene segments with other IAVs of different subtypes or clades infecting the same cell, called reassortment (14), which frequently occurs in pigs. A reassortant IAV with an antigenically novel HA and the capacity to infect and spread in humans could cause a pandemic.
Since 2010, 35 zoonotic infections with H1 swIAVs were reported in North America and 10 in Europe (1517; Parys et al., unpub. data). Human population immunity is a major factor determining the pandemic risk for swIAVs. Hemagglutination inhibiting (HI) and virus neutralizing (VN) antibodies in serum are accepted correlates of protection (18). Evaluating humans of different age groups for HI and VN antibody titers against a range of antigenically different swIAVs might help clarify the public health risk.
In a previous seroprevalence study for H3 swIAVs in humans from Luxembourg, we demonstrated a correlation with the nature of the swIAV and its relation to human IAVs on the one hand and the persons birth year on the other (19). A large comparative seroprevalence study for H1 swIAVs is lacking. Previous studies examined limited numbers of H1 swIAVs or samples or did not evaluate the relation between birth year and antibody responses (12,13,2025). In addition, most studies were conducted before or during the 2009 pandemic, but the circulation of pH1N1 viruses in humans likely changed the serologic profile against H1 swIAVs. We assessed prevalence and titers of protective antibodies against all major H1 swIAV clades in various age groups in Belgium in 2017. We also examined the relation between antibodies against human-like swIAVs and their presumed human seasonal ancestor IAV. The results will help assess the public health risk for different H1 swIAVs.
During August 2017January 2018, a total of 549 anonymized serum samples were collected from immunocompetent persons with unknown influenza vaccination or infection history born during 19202017 at Ghent University Hospital (Ghent, Belgium). Samples included 6 per birth year with 1:1 ratio between male and female patients. Exclusion criteria included active oncologic disease or hematologic malignancies, immunosuppressive treatment, organ transplantation, admission to intensive care, and end-stage renal disease on dialysis treatment. This study was approved by the Commission for Medical Ethics of the Ghent University Hospital (approval no. 2017/0834).
Samples were evaluated for antibodies against 11 viruses representing 7 major H1 swIAV clades circulating in Europe, North America, and Asia; 2 human seasonal progenitor IAVs for European and North American human-like swIAVs; and 1 human seasonal IAV that circulated right before the pH1N1 virus (Table 1). We used epidemiologic data (1012) and the H1 classification system (9) to select major H1 swIAV clades. We selected test viruses on the basis of amino acid homology and antigenic relatedness to currently circulating swIAVs of each clade. We selected the human progenitor IAVs based on the literature (26,27).
We downloaded nucleotide sequences of the viruses HA1, the main target of neutralizing antibodies, from Genbank and translated these to amino acids. We used the MUSCLE algorithm for sequence alignment and the Jones-Taylor-Thornton model and nearest-neighbor-interchange heuristic method to construct maximum-likelihood trees in MEGA7 (28). We determined the percent of amino acid homology between test viruses and numbers of identical amino acids in presumed antigenic sites (29) with MEGA7 and R version 3.2.2 (30).
We obtained North American swIAVs and corresponding swine serum from the U.S. Department of Agriculture-Agricultural Research Service. We obtained human seasonal IAVs and corresponding ferret serum from Francis Crick Institute (London, UK), and Asian swIAV from Hong Kong University (Hong Kong). We antigenically characterized test viruses in cross-HI and cross-VN assays with postvaccination swine serum for swIAVs or postinfection ferret serum for human seasonal IAVs. Because serum against A/Brisbane/59/2007 was not available, we used ferret serum against A/Egypt/10/2007 instead; the HA sequence is identical in both. We propagated viruses in MDCK cells; all passages were <6. We calculated antigenic distances from HI and VN titers as described previously (31) and converted these into antigenic dendrograms by using the neighbor-joining method in MEGA7. One antigenic unit represents a 2-fold difference in HI or VN titer.
We tested individual samples in HI assays and pooled samples per birth year in VN assays for antibodies against each test virus. Both assays were performed according to standard procedures (32,33). We expressed antibody titers for HI as the reciprocal of the highest serum dilution showing complete hemagglutination inhibition of 4 hemagglutinating units of virus or, for VN, 50% neutralization of 100 TCID50 (50% tissue culture infective doses) of virus. The starting dilution was 1:20, and we considered a titer of 40 positive.
We calculated geometric mean titers (GMTs) and 95% CIs for HI and VN antibody titers of samples from each birth decade against each test virus by using log2-transformed data. Samples with a titer <20 were assigned a titer of 10. For non-stratified data, we calculated Spearman correlation coefficients (CCs) between HI titers or between VN titers against different viruses. We used Kruskal-Wallis and Mann-Whitney U tests to compare antibody titers between age groups for a certain virus or between viruses for a certain age group. We used Fisher exact test to compare proportions of positive samples. For all statistical tests, we applied Bonferroni adjustment of the p values and we considered corrected p values of <0.05 statistically significant. We performed all analyses by using R version 3.2.2.
Figure 1
Figure 1. Epidemiologic, phylogenetic, and antigenic relationship between influenza A test viruses from classical swine lineage 1A, human seasonal lineage 1B, and Eurasian avian lineage 1C. A) Schematic representation of the H1 IAV...
We tested samples for antibodies against 11 IAVs from the classical swine 1A, human seasonal 1B, or Eurasian avian 1C lineage. HA1 aa sequence homology between viruses of different lineages was <75% with 1935/50 identical amino acids in presumed antigenic sites. Classical swine and avian-like IAVs were phylogenetically most closely related (Figure 1, panel A; Table 2). Within-lineage HA1 aa homology was 82%97%, with 3649 identical amino acids in antigenic sites. Human-like swIAVs and their presumed human seasonal progenitor IAV shared 90%94% aa in the HA1 and 3642 aa in antigenic sites.
Antigenic dendrograms based on cross-HI and cross-VN assays showed similar trends to the phylogenetic tree, except for swOK13 (Tables 35; Figure 1). This North American human-like 1b swIAV (1B.2.2.2) clustered separately from other IAVs of its lineage, including its presumed human ancestor, NC99.
Figure 2
Figure 2. Number of positive human serum samples in the hemagglutination inhibition assay (titer >40) for each test virus compared with the total number of samples tested per birth cohort. Birth cohorts...
Figure 3
Figure 3. Number of positive human serum samples in the virus neutralization assay (titer >40) for each test virus compared with the total number of samples per birth cohort. Birth cohorts are...
We tested human serum samples against human seasonal IAVs related to 1B swIAVs from 1986 (TW86), 1999 (NC99), and 2007 (BR07) to evaluate a persons potential exposure to or vaccination with these IAVs. Overall, 39% were seropositive for TW86, 31% for NC99, and 22% for BR07 in HI and 48% were seropositive for TW86, 51% for NC99, and 29% for BR07 in VN (Figures 2, 3). Seroprevalences and GMTs against TW86 were highest for persons born during 19771986 and lowest for the 2 youngest groups, those born during 19972017 (Tables 6, 7). For NC99 and BR07, HI responses were highest for those born during 19871996, and VN responses were highest for those born during 19371946 (NC99 only) and 19972006. Persons born during 20072017 had minimal responses. Antibody responses against human seasonal IAVs were related to birth year and the year of virus isolation, with peak responses in persons born right before the virus circulated and lowest responses in persons born afterwards.
The major avian-origin swIAV clades are European avian-like 1C.2.1, represented by swG10, and Asian avian-like 1C.2.3, represented by swHK11. For swG10, 10% of all samples tested positive in HI and 7% in VN (Figures 2, 3). Seroprevalence was <20% and GMTs were <20 for all age groups except the oldest, those born during 19201926, with 40% seropositive in HI and GMTs for HI and VN of 24 (Tables 6, 7).
For swHK11, overall seroprevalence was 25% in HI and 34% in VN. Like swG10, responses against swHK11 were highest for those born during 19201926; 52% in HI, 72% in VN, and GMTs 38. Responses were minimal in both HI and VN for persons born during 19471956; 11% in HI, 10% in VN, and GMTs <20.
European human-like swIAV swG12 (1B.1.2.1) represents the human-like H1 swIAV clade circulating in Belgium, and TW86 was selected as its presumed human ancestor virus. At least half of all samples tested positive for swG12, 50% in HI and 59% in VN (Figures 2, 3). We noted statistically significant differences in seroprevalences and GMTs, which were higher (62% in HI and 74% in VN; GMTs 44) in persons born before 1996 than in persons born during 19972017 (5% in HI and in VN; GMTs <20; p<0.001) (Tables 6, 7). GMTs peaked (87) in HI in those born during 19771986 and in VN for those born during 19671976. Results for swG12 were similar to those for its presumed human ancestor virus, TW86.
North American human-like H1 swIAVs (1B.2) result from the introduction of a human IAV in the early 2000s, and we selected NC99 as their presumed human ancestor. For the most prevalent 1 clade (1B.2.2), swAL16 represents subclade 1a (1B.2.2.1), whereas swIL10 and swOK13 represent subclade 1b (1B.2.2.2).
Among samples, 24% tested positive for swAL16 in HI and 39% in VN (Figures 2, 3). Seroprevalences and GMTs were highest in those born during 19871996 in HI (55%; GMT 35) and in those born during 19471956 in VN (70%; GMT 59), but no antibodies against swAL16 were detected in the youngest group, those born during 20072017 (Tables 6, 7). Like for European human-like virus swG12 (1B.1.2.1), antibody responses against North American 1a virus swAL16 (1B.2.2.1) resembled those against its presumed human ancestor virus, NC99.
For the 1b swIAVs (1B.2.2.2), <10% were seropositive (swIL10, 10% in HI and VN; swOK13, 5% in HI and 4% in VN) (Figures 2, 3). We did not see statistically significant differences in seroprevalences between the 2 1b swIAVs or between age groups, with following exceptions. HI-seroprevalence of those born during 19271936 was statistically significantly higher for swIL10 (13%) than for swOK13 (2%; p<0.04). HI seroprevalence for swOK13 of those born during 19771986 was statistically significantly higher (21%) compared with groups born during 19271936 (2%), 19571966 (0), and 20072017 (0; p<0.04). GMTs were <20 in all age groups except those born during 19371956, who had VN GMTs of 2230 against swIL10 (Tables 6, 7). Unlike the other 2 human-like swIAVs tested, responses against 1b swIAVs (1B.2.2.2) did not concur with those against the presumed human ancestor virus NC99. Responses against swIL10 and swOK13 were generally statistically significantly lower than against NC99 (p<0.05).
We used swOH07 as reference virus to evaluate antibody responses against classical swine virus clade (1A.3.3.3) and CA09 as reference virus to evaluate classical swine virus clade pH1N1 (1A.3.3.2), which derived its HA from swIAVs. Overall, 50% of the samples tested positive for swOH07 (50% in HI; 78% in VN) and CA09 (54% in HI; 81% in VN), with high seroprevalences in all age groups (36%100% in HI; 50%100% in VN), except in those born during 19471956 in HI (swOH07, 17%; CA09, 24%) (Figures 2, 3). HI titers peaked in the 2 oldest groups, those born during 19201936; VN titers peaked in the 2 oldest groups and in those born during 19972006 (Tables 6, 7). No statistically significant difference was noted in responses against classical swine (1A.3.3.3) and pH1N1 (1A.3.3.2) IAVs.
Antibody titers against epidemiologically related human and swine IAVs were highly correlated for classical swine viruses swOH07 (1A.3.3.3) and CA09 (1A.3.3.2), European human-like swIAV swG12 (1B.1.2.1) and human ancestor IAV TW86, North American human-like 1a swIAV swAL16 (1B.2.2.1) and human ancestor IAV NC99, and European and Asian avian-like swIAVs swG10 (1C.2.1) and swHK11 (1C.2.3) (CC=0.680.86 in HI; CC=0.630.77 in VN; Table 8). Of note, titers against avian-like and classical swine IAVs also were strongly correlated (CC=0.550.68 in HI; CC=0.490.67 in VN). In contrast, CCs were low between titers against North American human-like 1b viruses swIL10 and swOK13 (1B.2.2.2) and human ancestor virus NC99 (0.420.43 in HI; 0.300.39 in VN [the first value of which is not statistically significant]).
Our results show that serum antibody responses of immunocompetent persons in Belgium against major H1 swIAV clades depend on the swIAV tested and its relation to human seasonal IAVs and the persons birth year. Overall seroprevalences were high (50%) for classical swine (1A.3.3.2, 1A.3.3.3) and for European human-like (1B.1.2.1) swIAVs, intermediate (24%) for North American human-like 1a (1B.2.2.1) and Asian avian-like (1C.2.3) swIAVs, and low (<10%) for North American human-like 1b (1B.2.2.2) and European avian-like (1C.2.1) swIAVs. Our results are consistent with previous studies that aimed to compare antibody responses in nonswine workers with those in persons with frequent swine contact (7,2025), although those studies examined only a limited number of swIAV clades or samples. Overall, most previous studies showed lower seroprevalences for Asian avian-like (2%10%) and European avian-like (05%) swIAVs in the general population or in nonswine workers (13,20,2224). A 2010 study in the United Kingdom also found a lower seroprevalence of 11% for a European human-like (1B.1.2.1) swIAV (24). The major difference between our study and studies conducted before or during the 2009 pandemic is the lower seroprevalence of 3%15% for classical swine IAVs in previous studies (13,20,2224). The circulation of pH1N1 viruses (1A.3.3.2) likely contributes to increased seroprevalence rates against these related classical swine IAVs. In our study, the oldest group, those born during 19201926 who are 9197 years of age, had the highest antibody responses against H1 swIAVs of classical swine (1A.3.3) and avian-like (1C.2) lineages, for which antibody titers were correlated (13,20,21). Responses against human seasonal IAVs and related European and North American 1a human-like H1 swIAVs (1B) generally were highest in those born during 19771996, who are 2140 years of age, and lowest in those born during 19962017, who are 020 years of age. Responses against North American 1b human-like H1 swIAVs (1B.2.2.2) generally were low across all age cohorts.
Antibody responses against past human seasonal IAVs TW86, NC99, and BR07 generally peaked in persons born near the time during which the respective IAV or similar viruses circulated, whereas responses were low in most persons born after. Within an age group, responses generally were highest against an antigenic representative of the virus encountered first. These findings concur with the theory of antigenic seniority: humans are expected to have antibodies against human seasonal IAVs that circulated after their birth, with highest responses against the virus encountered first. Antigenic seniority likely occurs because of periodic boosting of these antibodies by subsequent exposures to related human seasonal IAVs (4,34,35). Antibody titers against European human-like swIAV swG12 (1B.1.2.1) and North American human-like 1a swIAV swAL16 (1B.2.2.1) concur with those against their respective human ancestor viruses TW86 and NC99 because of close antigenic relationship to their ancestor IAV. Overall high seroprevalences against pH1N1 virus CA09 (1A.3.3.2) and antigenically closely related classical swine virus swOH07 (1A.3.3.3) can be explained by recent exposure to currently circulating pH1N1 viruses. Because the oldest persons were born during 19201936, when human IAVs closely related to the 1918 pandemic virus, the ancestor of classical swine IAVs, circulated, they could have had cross-reactive antibodies against classical swine IAVs before 2009. These antibodies might have been boosted by later exposure to pH1N1 viruses, which might account for the high responses in this group (6,7). Consistent with results for serum samples collected after pH1N1 virus infection in a previous study (21), cross-reactivity was higher against the Asian than against the European avian-like H1 swIAV, which differ by only 1 aa in antigenic sites (Table 2). Whether this single amino acid mutation is the reason for the difference in seroprevalence is still unknown (36,37).
European human-like (1B.1.2.1) and North American human-like 1a (1B.2.2.1) H1 swIAVs are antigenically more closely related to their human ancestor than North American human-like 1b (1B.2.2.2) H1 swIAVs (Figure 1; Tables 3, 4). North American human-like H1 swIAVs (1B.2) have been shown to drift 4 times faster than European human-like H1 swIAVs (1B.1). Increased antigenic diversity of the former since 2008 has led to the emergence of swIAVs that are antigenically distinct from the human precursors, mainly within the 1b subclade (3,27). This evolution can explain the recognition of selected European human-like and North American human-like 1a but not North American human-like 1b H1 swIAVs by human serum samples. Because the human ancestor IAVs no longer circulate in humans, swine can be considered a reservoir for old human IAVs. Seroprevalences for European human-like and North American human-like 1a H1 swIAVs are expected to decrease over time because the youngest age groups were never exposed to these human IAVs. On the basis of our results, we estimate that it could take <80 years for the population to become fully susceptible.
Seroprevalences of immunocompetent persons in Belgium for swIAVs representing major H1 swIAV clades suggest that North American human-like 1b (1B.2.2.2) and European avian-like (1C.2.1) H1 swIAVs currently pose the highest risk to public health. North American human-like 1b (1B.2.2.2) swIAVs rapidly drifted away from its human ancestor, whereas European avian-like (1C.2.1) swIAVs never circulated in humans. Seroprevalences of <10% for these viruses are comparable to 2%19% against the pH1N1 virus right before the pandemic (7). Our results suggest that the risk of reintroduction of these H1 swIAVs in the human population might be higher than for H3 swIAVs, given that 20% of persons 0100 years of age from Luxembourg tested seropositive for representative European and North American cluster IV H3 swIAVs in 2010 (19). Seroprevalences against the other currently circulating human-like H1 swIAV clades were higher than against 1B.2.2.2 and 1C.2.1, but these viruses, along with H3 swIAVs, also keep evolving in swine. As they continue to drift away from their human ancestor and population immunity wanes with lack of exposure, these viruses might also pose a risk to public health soon.
We evaluated human population immunity against H1 swIAVs on the basis of serum HI and VN antibodies, which are directed against the highly variable head region of the HA. We did not measure antibodies or T-cell responses against the HA stalk, the neuraminidase, or internal viral proteins, such as the nucleoprotein. Although these immune mechanisms are much less potent than neutralizing anti-HA antibodies, their targets are more conserved between IAVs of humans and swine (3842). Therefore, persons with minimal antibody titers in our study still might have some degree of immunity and protection against zoonotic infection with swIAVs. Furthermore, population immunity is only one aspect determining the pandemic potential of swIAVs (18). Another factor is their ability to spread in humans, which is difficult to investigate (43). Our results stress the need for continuous surveillance and characterization of circulating swIAVs and frequent monitoring of humans for antibodies against these swIAVs.
Ms. Vandoorn was a PhD student at the Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, during the study period. Her primary research interests are swine influenza A virus surveillance in Belgium and the Netherlands and broadly protective vaccination strategies for influenza A viruses.
Top
Suggested citation for this article: Vandoorn E, Leroux-Roels I, Leroux-Roels G, Parys A, Vincent A, Van Reeth K. Detection of H1 swine influenza A virus antibodies in human serum samples by age group. Emerg Infect Dis. 2020 Sep [date cited]. https://doi.org/10.3201/eid2609.191796
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
View original post here:
Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age Group - CDC
- June 11th At Westport, CT: Federal Red Flags, HIPAA Security Rules and Fraud Prevention [Last Updated On: November 7th, 2009] [Originally Added On: November 7th, 2009]
- Do not learn Dvorak! [Last Updated On: November 7th, 2009] [Originally Added On: November 7th, 2009]
- You Can’t Solve Problems By Making It Illegal To Have The Problem [Last Updated On: November 7th, 2009] [Originally Added On: November 7th, 2009]
- A Force Fix for Healthcare [Last Updated On: November 7th, 2009] [Originally Added On: November 7th, 2009]
- Yahble, HIT, Bubblecon, BIZDEV!, Solid State [Last Updated On: November 7th, 2009] [Originally Added On: November 7th, 2009]
- 15 things that suck about the Palm Pre [Last Updated On: November 7th, 2009] [Originally Added On: November 7th, 2009]
- What an Indie Genomics Lab Looks Like [Last Updated On: November 7th, 2009] [Originally Added On: November 7th, 2009]
- Practice Fusion: Class D Felony? [Last Updated On: February 26th, 2010] [Originally Added On: February 26th, 2010]
- Practice Fusion Responds [Last Updated On: March 7th, 2010] [Originally Added On: March 7th, 2010]
- Practice Fusion: Do the math: $44,000 is a LIE [Last Updated On: March 10th, 2010] [Originally Added On: March 10th, 2010]
- How Much Until Doctors Approve of 23andMe? [Last Updated On: March 10th, 2010] [Originally Added On: March 10th, 2010]
- Biochemicals as Media, Not Methods [Last Updated On: March 10th, 2010] [Originally Added On: March 10th, 2010]
- More Practice Fusion Reality Distortion [Last Updated On: March 10th, 2010] [Originally Added On: March 10th, 2010]
- Same Test Results: 23andMe is Myriad is BRCA is Medicine [Last Updated On: March 12th, 2010] [Originally Added On: March 12th, 2010]
- BRCA is 23andMe is Myriad is Medicine [Last Updated On: March 13th, 2010] [Originally Added On: March 13th, 2010]
- Getting Serious About Genomics as Common Medical Practice [Last Updated On: March 15th, 2010] [Originally Added On: March 15th, 2010]
- The New John Mackey of Genetics: Linda Avey? [Last Updated On: March 15th, 2010] [Originally Added On: March 15th, 2010]
- Keep the Medical, Well, Medical [Last Updated On: March 16th, 2010] [Originally Added On: March 16th, 2010]
- If 23andMe shuts down, it won’t be for some mundane reason like the bills weren’t paid [Last Updated On: March 16th, 2010] [Originally Added On: March 16th, 2010]
- If I Run A Medical Practice, How Do I Use A 23andMe? [Last Updated On: March 17th, 2010] [Originally Added On: March 17th, 2010]
- 23andMe Contract in Bad Faith [Last Updated On: March 19th, 2010] [Originally Added On: March 19th, 2010]
- Doctors CANNOT Use 23andMe Due To 23andMe’s Bad Faith Contract [Last Updated On: March 20th, 2010] [Originally Added On: March 20th, 2010]
- Pathway Compared to 23andMe and Navigenics [Last Updated On: March 22nd, 2010] [Originally Added On: March 22nd, 2010]
- There’s a Word for “Views Differ” When One View Is The State [Last Updated On: March 24th, 2010] [Originally Added On: March 24th, 2010]
- Association for Molecular Pathology, et al. v. USPTO, et al. – Opinion [Last Updated On: March 29th, 2010] [Originally Added On: March 29th, 2010]
- Birth of a Super Villain [Last Updated On: April 3rd, 2010] [Originally Added On: April 3rd, 2010]
- “Medical Products” like 23andMe must not become the new “Financial Products” [Last Updated On: April 4th, 2010] [Originally Added On: April 4th, 2010]
- How I Would Apply Genomic Technology In Clinical Use Today [Last Updated On: April 5th, 2010] [Originally Added On: April 5th, 2010]
- Gmail Enterprise: World’s Best EMR [Last Updated On: April 6th, 2010] [Originally Added On: April 6th, 2010]
- Brief Primer on Health Law Compliance [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- Spoiler: You ARE the “Valids” [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- Rachel Lehmann-Haupt Line by Line Take Down [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- Is Medicare Bankrupt? What the Hell Is Going On? [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- The Big Shuffle: Medicare Cuts Rates by 21.3% (but not “technically”) [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- “Tech Hiring Binge” == “Fear for Your Job, Nerds” [Last Updated On: April 18th, 2010] [Originally Added On: April 18th, 2010]
- How Bad is Bad? $.20 on the Private Medical Insurance Dollar [Last Updated On: April 20th, 2010] [Originally Added On: April 20th, 2010]
- Update: How Bad is Bad? It Used to Be $.45 on the Medical Insurance Dollar [Last Updated On: April 20th, 2010] [Originally Added On: April 20th, 2010]
- World’s Best “EMR” for $1000: Google Spreadsheets + iPad [Last Updated On: April 21st, 2010] [Originally Added On: April 21st, 2010]
- Don’t Insult Me with your “AOL Keyword” Strategy, Google Health [Last Updated On: April 21st, 2010] [Originally Added On: April 21st, 2010]
- How to Play LAWGAMES [Last Updated On: April 23rd, 2010] [Originally Added On: April 23rd, 2010]
- Top 4 Predatory Schemes Encroaching on American Medicine: Part 1 [Last Updated On: April 25th, 2010] [Originally Added On: April 25th, 2010]
- What’s the Big Deal About iPads? [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- Got Google Android for Google I/O [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- Google Enterprise meets HIPAA and HITECH Compliant Laws [Last Updated On: April 29th, 2010] [Originally Added On: April 29th, 2010]
- Pixels of Accuracy CHALENGE: Diagnostic Medical Imaging [Last Updated On: April 29th, 2010] [Originally Added On: April 29th, 2010]
- 23andMe Launder AlioGenetics Doesn’t Even Bother to Remove 23andMe Logo [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- Anthem of CT Denies $600 Until “Subscriber Responds to our Coordination of Benefits Questionnaire” [Last Updated On: May 1st, 2010] [Originally Added On: May 1st, 2010]
- Apple And Google Team Up To Launch Revolutionary Mobile Health System [Last Updated On: May 1st, 2010] [Originally Added On: May 1st, 2010]
- Funny Pictures from This Year Building the Medical Practice [Last Updated On: May 6th, 2010] [Originally Added On: May 6th, 2010]
- Remote Medical Video Monitoring on iPad and iPhone [Last Updated On: May 7th, 2010] [Originally Added On: May 7th, 2010]
- Google Calendar Overhead Waiting Room Display [Last Updated On: May 7th, 2010] [Originally Added On: May 7th, 2010]
- Various Whiteboards on Solid State Medical Operations [Last Updated On: May 7th, 2010] [Originally Added On: May 7th, 2010]
- The Raw Facts about Counsyl [Last Updated On: May 7th, 2010] [Originally Added On: May 7th, 2010]
- Brawndo: Still Mutilating Thirst, Still Not Yet Sold at the Stop-n-Shop Pharmacy [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- Video: Google Enterprise to Outsource Medical Administration [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- Gattaca: “The Matrix” of Genomics [Last Updated On: May 11th, 2010] [Originally Added On: May 11th, 2010]
- 23andMe Now Diagnoses Fatal Tay-Sachs Disease [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- Why Was Pathway Targeted for FDA Enforcement and Not 23andMe? [Last Updated On: May 15th, 2010] [Originally Added On: May 15th, 2010]
- John Dolan on Aging and the Horrifying Conclusion of GWAS [Last Updated On: May 16th, 2010] [Originally Added On: May 16th, 2010]
- Sam R. Riley Wants To Tell You About Practice Fusion [Last Updated On: May 17th, 2010] [Originally Added On: May 17th, 2010]
- Response to “Genomic Medicine: Lost” [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- Death And Taxes: CMS to IRS [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- Please Stop Antagonizing the AMA [Last Updated On: May 26th, 2010] [Originally Added On: May 26th, 2010]
- Dan Vorhaus, Attorney At Law, Legally Advises Medical Doctors Can Use 23andMe To Provide Medical Advice [Last Updated On: May 28th, 2010] [Originally Added On: May 28th, 2010]
- Singularity Summit 2010 in San Francisco to Explore Intelligence Augmentation [Last Updated On: June 7th, 2010] [Originally Added On: June 7th, 2010]
- OpenPCR: DNA amplification for anyone [Last Updated On: June 10th, 2010] [Originally Added On: June 10th, 2010]
- FDA sends letters to 5 genetic testing companies [Last Updated On: June 11th, 2010] [Originally Added On: June 11th, 2010]
- Amazon And The NIH Team Up To Put Human Genome In The Cloud [Last Updated On: March 31st, 2012] [Originally Added On: March 31st, 2012]
- ReproSource Comments on New Study Linking Infertility to Genetics [Last Updated On: April 25th, 2012] [Originally Added On: April 25th, 2012]
- Genetics 101 Part 1: What are genes? - Video [Last Updated On: April 30th, 2012] [Originally Added On: April 30th, 2012]
- Red Ice Radio - David Icke - Hour 1 - The Manipulation of Humanity - Video [Last Updated On: April 30th, 2012] [Originally Added On: April 30th, 2012]
- Genetics Part 5: Human Genetic Disorders - Video [Last Updated On: April 30th, 2012] [Originally Added On: April 30th, 2012]
- C2CAM - The Nephilim, Genetic Manipulation [Last Updated On: April 30th, 2012] [Originally Added On: April 30th, 2012]
- Human Nature talk with Robert Sapolsky, Gabor Mate, James Gilligan, Richard Wilkinson - Video [Last Updated On: April 30th, 2012] [Originally Added On: April 30th, 2012]
- Human Genetic Diseases - Video [Last Updated On: April 30th, 2012] [Originally Added On: April 30th, 2012]
- Alien Scientist on Genetics, Implants [Last Updated On: April 30th, 2012] [Originally Added On: April 30th, 2012]
- Research and Markets: Genetics, 6th Edition International Student Version Continues To Educate Today's Students for ... [Last Updated On: May 4th, 2012] [Originally Added On: May 4th, 2012]
- Myriad Genetics to Present at the Bank of America Merrill Lynch 2012 Health Care Conference [Last Updated On: May 4th, 2012] [Originally Added On: May 4th, 2012]
- Genetics may explain some people's dislike of meat [Last Updated On: May 4th, 2012] [Originally Added On: May 4th, 2012]
- 'Blond Genes' May Vary Around the World [Last Updated On: May 4th, 2012] [Originally Added On: May 4th, 2012]